Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2018-11-22 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
第二届董事会第二十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board of directors meeting of 贝达药业股份有限公司 (Betta Pharmaceuticals Co., Ltd.). It includes information about the meeting's convening, attendance, agenda items, voting results, and references to stock option incentive plans and upcoming shareholder meetings. The content focuses on board decisions and management matters, specifically related to stock option plans and authorization for the board to act on these plans. There is no financial data, earnings information, or regulatory filings of financial results. The document is not a full annual or interim report, nor is it a call transcript or investor presentation. It is not a simple announcement of a report publication but a substantive board meeting resolution announcement. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is under 5,000 characters, but the content is substantive and not merely an announcement of a report publication, so it is not RPA or RNS.
2018-11-22 Chinese
浙江天册律师事务所关于公司2018年（第二期）股票期权激励计划的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding a 2018 stock option incentive plan of a listed company, 贝达药业股份有限公司. It extensively discusses the legal compliance, procedures, and qualifications related to the stock option plan, including references to relevant laws, regulations, and company governance. The document is not a financial report, earnings release, or management discussion but a legal opinion on a specific corporate action (stock option incentive plan). It is not an announcement of voting results or a proxy statement but a formal legal opinion letter. This type of document fits best under the category of Regulatory Filings (RNS), as it is a compliance/legal document related to corporate governance and regulatory requirements but does not fit into other more specific categories like MANG or DEF 14A. The document length (9100 characters) and content confirm it is a full legal opinion, not a brief announcement or certification. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2018-11-22 Chinese
2018年（第二期）股票期权激励计划激励对象名单
Remuneration Information Classification · 95% confidence The document is titled as a list of incentive stock option recipients for the year 2018, specifically for the second phase of the stock option incentive plan. It lists detailed names and roles of directors, senior management, and core technical/business personnel along with the number of stock options granted. This is a detailed disclosure related to stock option grants to management and employees, which is typically categorized under Remuneration Information filings. There is no indication that this is a full annual report, audit report, or other financial report. The document is not a brief announcement or a proxy solicitation but a detailed list of stock option incentives. Therefore, the most appropriate classification is Remuneration Information (DEF 14A). The document length (6276 characters) supports it being a substantive report rather than a short announcement.
2018-11-22 Chinese
关于召开2018年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening a 2018 second extraordinary general meeting of shareholders for Betta Pharmaceuticals Co., Ltd. It includes information about the meeting date, agenda items (stock option incentive plan proposals), voting procedures (both in-person and online), registration details, and attachments such as proxy forms and voting instructions. There are no financial statements or earnings data presented. The document is not a report itself but a formal announcement and invitation to shareholders to participate and vote on specific proposals at the meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings.
2018-11-22 Chinese
第二届监事会第二十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 21st meeting of the second Supervisory Board of Betta Pharmaceuticals Co., Ltd. It details the meeting's convening, attendance, and voting results on several agenda items, including the election of the Supervisory Board chairman and approval of a stock option incentive plan draft and related management measures. The document does not contain financial statements or detailed financial data but rather reports on governance decisions and supervisory board approvals. It is not an annual report, audit report, earnings release, or any financial report. It is also not a proxy solicitation or voting results announcement. The content aligns with announcements related to board or management information, specifically supervisory board resolutions and governance-related decisions. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is under 5,000 characters and is a full announcement, not a brief notice of report publication, so it is not RPA or RNS.
2018-11-22 Chinese
2018年（第二期）股票期权激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled as the "2018 (Second Phase) Stock Option Incentive Plan Implementation Assessment Management Measures" of Betta Pharmaceuticals Co., Ltd. It details the purpose, principles, management institutions, assessment periods, assessment objects, content and indicator systems, procedures, and results related to the stock option incentive plan. The document is a policy or management guideline related to the implementation and assessment of a stock option incentive plan, including performance targets and assessment criteria for management and key personnel. It does not contain financial statements, earnings data, or audit results. It is not an announcement of a report, nor a transcript, nor a regulatory filing about voting or management changes. It is a governance-related document about internal incentive plan management and assessment. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 3750 characters, which is relatively short but contains substantive governance content, not just an announcement or certification.
2018-11-22 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.